- Vera Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results
- Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Vera Therapeutics Announces Two Oral Presentations at the 61st European Renal Association Congress
- Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
- Vera Therapeutics to Participate at the 44th Annual TD Cowen Health Care Conference
- Vera Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
- Vera Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares in Public Offering of Class A Common Stock
- Vera Therapeutics Announces Pricing of Upsized Public Offering of Class A Common Stock
- Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock
- Vera Therapeutics Presents Positive 72-Week Data Showing eGFR Stabilization in the Phase 2b ORIGIN Clinical Trial OLE in IgA Nephropathy
More ▼
Key statistics
On Friday, Vera Therapeutics Inc (VERA:NMQ) closed at 41.39, -18.49% below its 52-week high of 50.78, set on Mar 01, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 42.11 |
---|---|
High | 42.26 |
Low | 40.92 |
Bid | 39.75 |
Offer | 41.25 |
Previous close | 41.94 |
Average volume | 635.55k |
---|---|
Shares outstanding | 54.45m |
Free float | 50.13m |
P/E (TTM) | -- |
Market cap | 2.25bn USD |
EPS (TTM) | -2.04 USD |
Data delayed at least 15 minutes, as of May 17 2024 21:00 BST.
More ▼